Sodium Phenylbutyrate; Taurursodiol Patent Expiration
Sodium Phenylbutyrate; Taurursodiol is Used for the treatment of Amyotrophic Lateral Sclerosis (ALS) in adults. It was first introduced by Amylyx Pharmaceuticals Inc
Sodium Phenylbutyrate; Taurursodiol Patents
Given below is the list of patents protecting Sodium Phenylbutyrate; Taurursodiol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Relyvrio | US11583542 | Compositions of bile acids and phenylbutyrate compounds | Jul 27, 2040 | Amylyx |
| Relyvrio | US10251896 | Compositions for improving cell viability and methods of use thereof | Dec 24, 2033 | Amylyx |
| Relyvrio | US10857162 | Compositions for improving cell viability and methods of use thereof | Dec 24, 2033 | Amylyx |
| Relyvrio | US11071742 | Compositions for improving cell viability and methods of use thereof | Dec 24, 2033 | Amylyx |
| Relyvrio | US9872865 | Compositions for improving cell viability and methods of use thereof | Dec 24, 2033 | Amylyx |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sodium Phenylbutyrate; Taurursodiol's patents.
Latest Legal Activities on Sodium Phenylbutyrate; Taurursodiol's Patents
Given below is the list recent legal activities going on the following patents of Sodium Phenylbutyrate; Taurursodiol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US10857162 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US11071742 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US10251896 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9872865 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US10857162 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US11071742 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US10251896 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US9872865 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US10251896 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US10857162 |
Sodium Phenylbutyrate; Taurursodiol's Family Patents
